Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
5.16
-0.06 (-1.15%)
At close: Nov 7, 2025, 4:00 PM EST
5.26
+0.10 (1.94%)
After-hours: Nov 7, 2025, 4:28 PM EST
Karyopharm Therapeutics Stock Forecast
KPTI's stock price has decreased by -61.2% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts that cover Karyopharm Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $29.71, which forecasts a 475.78% increase in the stock price over the next year. The lowest target is $10 and the highest is $75.
Price Target: $29.71 (+475.78%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Karyopharm Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Buy | 5 | 5 | 4 | 4 | 5 | 5 |
| Hold | 0 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $30 → $19 | Buy | Maintains | $30 → $19 | +268.22% | Nov 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $15 | Hold → Strong Buy | Upgrades | $15 | +190.70% | Oct 13, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $15 → $12 | Buy | Reiterates | $15 → $12 | +132.56% | Oct 9, 2025 |
| Baird | Baird | Buy Maintains $25 → $21 | Buy | Maintains | $25 → $21 | +306.98% | Oct 9, 2025 |
| Baird | Baird | Buy Maintains $42 → $25 | Buy | Maintains | $42 → $25 | +384.50% | Aug 12, 2025 |
Financial Forecast
Revenue This Year
152.31M
from 145.24M
Increased by 4.87%
Revenue Next Year
166.32M
from 152.31M
Increased by 9.20%
EPS This Year
-11.30
from -14.00
EPS Next Year
-5.71
from -11.30
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 160.5M | 180.6M | |||
| Avg | 152.3M | 166.3M | |||
| Low | 142.0M | 151.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.5% | 18.6% | |||
| Avg | 4.9% | 9.2% | |||
| Low | -2.2% | -0.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -7.47 | -2.44 | |||
| Avg | -11.30 | -5.71 | |||
| Low | -13.31 | -10.57 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.